Medicinova (MNOV) Stock: Buy, Sell, or Hold?
MNOV - Medicinova, Inc.
$1.78
0.15 (9.20%)
▲
5d:
-31.01%
30d:
+24.48%
90d:
+23.61%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When MNOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MNOV is down 31.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MNOV is down 31.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MNOV is currently trading at $1.78, which is considered fair relative to its 30-day fair value range of $1.36 to $2.67.
Technical Outlook: Technically, MNOV is in a uptrend. Immediate support is located at $1.63, while resistance sits at $3.40. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: MNOV scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+363.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNOV is in a uptrend. Immediate support is located at $1.63, while resistance sits at $3.40. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: MNOV scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+363.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.36 -
$2.67
Company Quality Score
39/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+9.2%)
- BULLISH: Trading 363.5% below Wall St target ($8.25)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.36 -
$2.67
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.63
Resistance Level
$3.40
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.46
Wall Street Target
$8.25
(+363.5%)
Revenue Growth (YoY)
240.6%
Share & Embed Analysis
Last updated: October 03, 2026 9:57 PM ET
Data refreshes hourly during market hours. Next update: 10:57 PM
Data refreshes hourly during market hours. Next update: 10:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
